Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.51 |
| ▸ | CTSD | P07339 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP8 | P22894 | 4/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418630 | 1.00 | MMP9 (0.51) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL6418631 | 1.00 | MMP9 (0.51) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL7301335 | 0.91 | MMP9 (0.60) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL7301330 | 0.91 | MMP9 (0.60) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL7174233 | 0.89 | FFAR1 (0.52) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL7174229 | 0.89 | FFAR1 (0.52) | MMP9CTSDMMP1MMP2MMP8 | |
| SCHEMBL4859637 | 0.83 | MMP9 (0.51) | MMP9MMP1MMP2MMP8ADAMTS4 | |
| SCHEMBL4861084 | 0.83 | MMP9 (0.51) | MMP9MMP1MMP2MMP8ADAMTS4 | |
| SCHEMBL23343881 | 0.80 | MMP9 (0.56) | MMP9MMP1MMP2MMP8ADAMTS4 | |
| SCHEMBL1177439 | 0.80 | MMP9 (0.53) | MMP9MMP1MMP2MMP8ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1434580-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003030886-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0708762-B1 | PROCESS FOR MAKING HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0541168-B1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO INC (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5717097-A | N-(2(R)-HYDROXY-1(S)-INDANYL)-2(R)-PHENYLMETHYL-4(S)-(HYDROXY) -5-SUBSTITUTED-N'-(T-BUTYLCARBAMOYL)PIPERAZINYL))PENTANEAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5668132-A | HIV Protease inhibitors useful for the treatment of AIDS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5527799-A | ADMINISTERING MIXTURE OF TWO COMPOUNDS AND OPTIONAL AZT | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5496948-A | REACTING AMIDE ENOLATE WITH GLYCIDOL DERIVATIVE; AMINATION | MERCK & CO., INC. (US) | 1996-03-05 | — | — | US | disclosed |
| US-5491238-A | Process for making HIV protease inhibitors | MERCK & CO., INC. (US) | 1996-02-13 | — | — | US | disclosed |
| US-5463067-A | Reacting glycidol or glycidyl tosylate with amide in presence of strong base at low temperature | MERCK & CO., INC. (US) | 1995-10-31 | — | — | US | disclosed |
| US-5413999-A | structure is piperazine containing amides | MERCK & CO., INC. (US) | 1995-05-09 | — | — | US | disclosed |
| WO-1994026717-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994022480-A1 | HIV PROTEASE INHIBITORS IN PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0617968-A1 | HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS | MERCK & CO. INC. (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1993009096-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0480714-A2 | HIV protease inhibitors having symmetrical structure | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | BACE1, BACE2, APBA1 | MMP9 869/4885CTSD 1038/4885MMP1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.